$VNDA News

Vanda (VNDA) Q2 2026 Earnings Call Transcript

B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12

HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate

Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S

Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis